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Introduction
Capecitabine, an oral prodrug of the chemotherapeutic 
5-fluorouracil (5-FU), is used in the treatment of 
advanced colorectal, esophageal, laryngeal, and 
breast cancers. 5-FU exerts its effects by blocking 
DNA synthesis through inhibition of the enzyme 
thymidylate synthetase, thereby sensitizing rapidly 
growing cells to cell death. Systemic use of 5-FU was 
long ago shown to result in skin photosensitivity, as 
well as an inflammatory reaction in actinic keratoses 
[1,2]. On this basis, it has been suggested that the 
anti-tumor activity observed by topical 5-FU on 
actinic keratoses is in part related to the production 
of an immunologic reaction in tandem with its 
anti-metabolite function [3]. Prodrugs of 5-FU (e.g. 
capecitabine) have also been reported to cause 
a variety of cutaneous eruptions [4-7] (Table 1). 
Herein, we describe a patient with a photosensitive 
lichenoid eruption developing during treatment with 
capecitabine and discuss our findings in the context 
of similar cases in the literature.
Case Synopsis
A 61-year-old woman with metastatic breast cancer 
presented to dermatology clinic for a three-week 
history of a progressive nonpruritic eruption on 
the arms. She reported the eruption started with 
pinpoint-sized erythematous macules that later 
evolved into scaly erythematous patches. One week 
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Table 1. Mucocutaneous side effects of Capecitabine. Table adapted with permission from Walker et al [6].
Hand-Foot syndrome Palmoplantar burning and erythema. Most common cutaneous reaction (7).
Nail toxicity Onycholysis and onychomadesis (4).
Stomatitis Tongue and buccal mucosa (6).
Subacute cutaneous
 lupus erythematosus
Photodistributed erythematous papules and plaques (6).
Miscellaneous Dermatitis, xerosis, alopecia, bullous eruptions (5).
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prior to the onset of this eruption, she had completed 
three consecutive 21-day cycles of capecitabine for 
breast cancer. Physical examination of the dorsum 
of the hands and forearms was remarkable for 
scattered variably sized erythematous patches and 
thin plaques with a small amount of peripheral scale 
(Figure 1). Serological testing for ANA was negative. 
A biopsy revealed basal layer vacuolization, a 
superficial and deep lymphocyte-rich inflammatory 
infiltrate that focally obscured the dermoepidermal 
junction, pigment incontinence, and scattered 
necrotic cells in the dermis (Figure 2). Based on 
these clinicopathologic findings, a diagnosis of 
capecitabine-induced (photosensitive) lichenoid 
eruption was made.
The patient was counseled regarding sun avoidance 
and protection and instructed to apply triamcinolone 
0.1% ointment twice daily to the affected areas. 
She remained off of capecitabine, initiated 
photoprotective measures, and started treatment 
with topical triamcinolone; at her one-month 
follow-up appointment, the patches and plaques 
were significantly smaller and less erythematous. 
After this visit, the patient resumed capecitabine 
and experienced a flare of her eruption along with 
a burning sensation in the involved areas. Physical 
exam during the flare revealed confluent pink to 
violaceous plaques on the dorsum of the hands 
and forearms. She denied any benefit of using 
triamcinolone ointment for the flare.
Discussion
Several types of drug eruptions are associated 
with 5-FU-based prodrugs like capecitabine. 
Hand-Foot syndrome (HFS), also known as 
palmar-plantar erythrodysesthesia, is the most 
common capecitabine-related adverse event and 
is observed in 45-68% of patients [8]. This eruption 
is characterized by palmoplantar erythema in 
conjunction with numbness, dysesthesia, and/
or paresthesia. Other mucocutaneous eruptions 
associated with capecitabine (Table 1) include nail 
and periungual reactions, oral lichenoid stomatitis, 
subacute cutaneous lupus erythematosus (SCLE), 
and capecitabine-induced lichenoid drug eruption 
[6,7,9].
It is interesting to note that despite the decades 
of use and many documented cases of cutaneous 
reactions after administration of 5-FU, there are, 
to our knowledge, no reported cases of lichenoid 
eruptions [10]. Lichenoid eruptions have been 
observed with the use of another 5-FU prodrug, 
Tegaful (1-(2-tetrahydrofuryl)-5-flurouracil) [11]. This 
would suggest that perhaps the lichenoid reaction 
seen with 5-FU prodrugs might in fact be related to a 
metabolite of the prodrugs rather than 5-FU.
To our knowledge, only three other cases of 
capecitabine-induced lichenoid drug eruption have 
been described in the literature [6,7,9]. Interestingly, 
all four reported cases of capecitabine-induced 
lichenoid drug eruption occurred in elderly women; 
the significance of this observation is unclear but 
Figure 1: Capecitabine-induced lichenoid drug eruption on 
dorsal forearm.
Figure 2: Haematoxylin and Eosin stain of biopsy displaying 
lymphocytic infiltrate and basal layer vacuolization. Original 
magnification 100x.
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notable. Our patient experienced some improvement 
upon drug discontinuation in conjunction with 
observation of photoprotective measures and 
application of topical corticosteroids. However, 
these latter interventions offered no significant 
benefit when the patient resumed therapy with 
capecitabine. Regarding previously reported cases, 
one patient experienced resolution of her eruption 
six weeks after discontinuation of capecitabine, 
whereas the other two demonstrated improvement 
with administration of topical steroids despite 
continuation of capecitabine [5,6,12]. Specifically, 
one of the patients observed an overall decrease 
in the number of lesions after topical halobetasol 
treatment [12], whereas the other patient noted 
improvement in her eruption with topical clobetasol 
and photoprotective measures; the nature of this 
improvement was not mentioned [6]. Our patient 
and those reported elsewhere in the literature 
suggest moderate potency topical corticosteroids 
and photoprotection have some therapeutic efficacy 
in patients with capecitabine-induced lichenoid drug 
eruption. These cases are reviewed in Table 2.
Table 2. Findings in previous cases of capecitabine-induced lichenoid eruption.
Age/
sex
Temporal 
association with 
capecitabine
Morphology Distribution Histology Labs Treatment
73/F 1 week after initi-ation
Erythematous 
plaques Neck and arms
Focal hyperker-
atosis including 
parakeratosis. 
Epidermal atro-
phy. Basal layer 
vacuolization. 
Perivascular lym-
phocytic infiltrate 
and pigment 
incontinence. 
DIF negative for 
Immunoglobulin 
and complement.
None re-
ported
Eruption resolved after 
discontinuing capecit-
abine (5).
56/F 2 weeks after initiation
Erythematous 
papules and 
plaques
Photodistribution 
on trunk and 
extremities
Occasional 
necrotic kerat-
inocytes. Basal 
layer vacuoliza-
tion Superficial 
and mid-dermal 
perivascular infil-
trate of uniform 
lymphocytes.
None re-
ported
Treatment with halo-
betasol, loratidine, 
and photoprotection, 
despite continuing 
capecitabine, reduced 
the extent of disease 
though new lesions 
continued to develop 
(12).
75/F 2 months after initiation
Violaceous pap-
ules and scaling 
erythema
Photodistribu-
tion on forearms, 
dorsal hands, and 
anterior aspect of 
legs. Also associat-
ed nail changes.
Compact or-
thokeratosis. 
Lichenoid inter-
face dermatitis. 
Scattered mela-
nophages and 
few eosinophils 
in dermis.
None re-
ported
Improvement noted 
with clobetasol 0.05% 
ointment, hydroxyzine, 
and photoprotection 
despite continuing 
capecitabine therapy 
(6).
61/F
1 week after com-
pleting a cycle of 
therapy
Erythematous 
patches with 
scale
Extensor forearms 
and dorsal hands
Basal layer vacu-
olization. Super-
ficial and deep 
lymphocyte-rich 
inflammatory 
infiltrate. Pigment 
incontinence 
and scattered 
necrotic cells in 
the dermis. 
ANA nega-
tive
Minimal improvement 
with triamcinolone 
0.1% ointment and 
photoprotection. The 
eruption improved 
with discontinuation of 
capecitabine and flared 
when treatment with 
capecitabine resumed 
(present case). 
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The differential diagnosis for capecitabine-induced 
lichenoid drug eruption includes capecitabine-
induced inflammation of actinic keratoses, which can 
present with pruritic, erythematous scaling macules 
and papules on sun-exposed areas of the skin [13]. 
In our case, both diagnoses were considered but 
examination of the biopsy findings conclusively 
ruled out the diagnosis of inflammation of actinic 
keratoses. Other diagnoses to consider include 
SCLE and erythema multiforme. Histologically, these 
entities do not typically display the broad lichenoid 
infiltrate that was seen in our patient’s biopsy 
specimen, but rather predominantly display vacuolar 
changes. The negative ANA further argues against 
SCLE, as previous studies have found that over 80% 
of drug-induced SCLE patients have positive ANA 
lab values [14]. Other histologic features present in 
this case that favor a lichenoid drug reaction include 
individual apoptotic keratinocytes located above the 
basal layer of the epidermis, the presence of plasma 
cells in the infiltrate, and pigment incontinence in 
the dermis.
Conclusion
In closing, we describe a rarely reported cutaneous 
adverse event of capecitabine and highlight other 
mucocutaneous adverse events associated with this 
and related medications.
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